Extended Interval Dosing and Dose Reductions of Rituximab in the Treatment of Multiple Sclerosis
Description
In this presentation, Dr. Gould will review current evidence supporting the use of extended interval dosing of low-dose rituximab.
Next-Generation Therapeutics in MS and Autoimmune Neurology*
Date: October 18, 2026
Time: 3:30 pm to 5:00 pm
Room: Seaglass
Track: Traditional Special Interest Group (SIG)
Session Description
The fields of multiple sclerosis (MS) and autoimmune neurology are rapidly evolving, with an expanding therapeutic landscape and increasing opportunities for precision treatment. In MS, B cell–targeted therapies have transformed disease management, offering high efficacy in reducing disease activity and preventing relapses. However, long-term immunosuppression raises important safety and cost considerations, and emerging evidence suggests that extended-interval dosing strategies may help mitigate these risks.
In myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), there are currently no approved therapies, but advances in neuromyelitis optica spectrum disorder have accelerated the development of targeted clinical trials, with early results now emerging alongside growing real-world data. In parallel, chimeric antigen receptor (CAR) T-cell therapy is gaining attention as a novel approach for treating autoimmune neurologic disorders of the central nervous system.
This session will highlight these evolving therapeutic strategies, focusing on current evidence, clinical application, and future directions in MS and autoimmune neurology.
Learning Objectives
At the conclusion of this session, attendees will be able to:
- Describe the role of extended-interval dosing strategies for B cell–targeted therapies in MS.
- Discuss current and emerging therapeutic approaches for MOGAD.
- Evaluate the potential risks and clinical applications of CAR T-cell therapy in autoimmune neurology.
Speakers
- (Chair) Eoin P. Flanagan, MD, FANA
- (Co-Chair) Rajesh Gupta, MD, MBBS, MS, FANA
- (Speaker) Annette Langer-Gould, MD, PhD
- (Speaker) Michael Levy, MD, PhD
- (Speaker) Giovanna Manzano, MD
MOGAD Therapeutics in 2026: Evidence, Trials, and Real-World Decisions
Description
In this presentation, Dr. Levy will discuss the latest evidence in the treatment of MOGAD.
CAR-T Treatments for Autoimmune CNS Neurologic Disorders
Description
In this presentation, Dr. Manzano will discuss clinical applications for chimeric antigen receptor (CAR) T-cell therapy in neuroimmunologic diseases, reviewing successes and limitations.